the RSV virion structure, key neutralizing epitopes on the pre- and post-fusion forms of the fusion protein and implications for vaccine development. CHF: Congestive heart failure; CLD ...

Scientists have long attempted to create vaccines that coax the immune system into recognizing the fusion (F) proteins ...

First, they must enter the host cells, which RSV does using its fusion (F) protein. Vaccines induce antibodies that bind to pathogens. Neutralizing antibodies bind to crucial sites, such as part ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

The acquisition focuses on sisunotavir, an RSV fusion inhibitor that UK-based ReViral ... including a follow-up RSV candidate targeting the viral N protein that is in phase 1 testing.

The trimeric pre-fusion glycoprotein F is essential for accurately assessing the immunogenicity of RSV vaccines. We strictly adhere to ... whether it comes through recombinant proteins, antibodies, ...

In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine. Variations in the F protein sequence among RSV-A ...

Future Virology. 2014;9(8):753-767. CHF: Congestive heart failure; CLD: Chronic lung disease; F: Fusion; G: Glyco; GLA-SE: Glucopyranosyl lipid A-stable emulsion; GMT ...